

Rec'd PCT/PTO 26 AUG 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number  
**WO 2004/015091 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N 5/00**
- (21) International Application Number:  
PCT/GB2003/003407
- (22) International Filing Date: 6 August 2003 (06.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0218332.5 7 August 2002 (07.08.2002) GB
- (71) Applicant (for all designated States except US): **NO-VATHERA LIMITED** [GB/GB]; 90 Fetter Lane, London EC4A 1JP (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BISHOP, Anne, Elizabeth** [GB/GB]; Tissue Engineering & Regenerative Medicine Centre, Faculty of Medicine - Imperial College London, Chelsea & Westminster Hospital, Fulham Road, London SW10 9NH (GB). **POLAK, Julia, Margaret** [GB/GB]; Tissue Engineering & Regenerative Medicine Centre, Faculty of Medicine - Imperial College London, Chelsea & Westminster Hospital, Fulham Road, London SW10 9NH (GB).
- (74) Agents: **MARSHALL, Cameron, John et al.**; Carpmiels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION OF TYPE II PNEUMOCYTES FROM STEM CELLS



(57) Abstract: Stem cells are induced in culture to form cells which express surfactant protein C (SPC), thereby offering a convenient and abundant supply of alveolar tissue without requiring lung donation or the use of cadavers. Stem cells are cultured to give embryoid bodies, which are then maintained under conditions which cause them to differentiate into cells which express SPC. SAGM medium has been found to be particularly effective for causing differentiation of the embryoid bodies.

WO 2004/015091 A2

BEST AVAILABLE COPY

## PREPARATION OF TYPE II PNEUMOCYTES FROM STEM CELLS

All documents cited herein are incorporated by reference in their entirety.

### TECHNICAL FIELD

This invention is in the field of lung biology, and more particularly alveolar epithelial cells.

### 5 BACKGROUND ART

The epithelium of the distal lung is highly specialised and is composed mainly of type I and type II pneumocytes. Type I alveolar epithelial (AE1) cells are particularly susceptible to damage and, following their loss during conditions of peripheral lung injury or disease, type II cells undergo a compensatory mechanism of proliferation and differentiation to a type I phenotype [1]. The alveolar  
10 type II (AE2) cell is also responsible for the synthesis and secretion of pulmonary surfactant, a complex mixture of phospholipids and proteins (*e.g.* surfactant protein C [2,3,4]) known to be critical for reducing surface tension at the air-liquid interface. Thus, type II cells are crucial to the natural regenerative process of the peripheral, gas-exchange component of the lung, and they have been described as defenders of the alveolus [5].

15 Because of their importance, the purification of AE2 cells has previously been the topic of active research. Reference 6 describes techniques for isolating and purifying AE2 cells from lung tissue. The purified cells are said to be useful for bioassay systems to monitor the effects of occupational or environmental pollutants on alveolar pneumocytes, and for studying the etiology of pulmonary disease in the alveolar region of the lung.

20 Other methods for purifying AE2 cells from lungs are described in references 7 to 10. Reference 9 suggests the transplantation of cells capable of regenerating lung alveolar surface for stimulating the growth of lung alveolar surface in patients.

AE2 cells thus have great potential both for therapeutic use and for investigating lung biology. Human cells are, however, in short supply as they can be prepared only from donated lung tissue.

25 Lung tissue which is surgically removed is normally diseased in AE2 cells and thus cadavers are the only realistic supply. It is an object of the invention to provide efficient methods for producing AE2 cells which do not require lung tissue donation or the use of cadavers.

### DISCLOSURE OF THE INVENTION

30 The invention is based on the finding that embryonic stem cells can be induced in culture to form cells which express surfactant protein C (SPC), which is a characteristic marker for AE2 cells [11], thereby offering a convenient and abundant supply of material for study and transplant.

Thus the invention provides a process for causing a stem cell to differentiate into a cell which expresses surfactant protein C, the process comprising the steps of: (a) culturing the stem cell to give an embryoid body; and (b) culturing the embryoid body under conditions which cause it to

differentiate into cells which express surfactant protein C. SPC<sup>+</sup> cells formed in this way can then be recovered from the culture medium.

### *Differentiation methods*

Step (a) of the process of the invention involves the formation of embryoid bodies (EBs). These are aggregates of cells which are formed when embryonic stem (ES) cells, embryonic germ (EG) cells, or embryonal carcinoma (EC) cells are grown in suspension culture (*e.g.* when plated on a non-adhesive surface). They are widely recognised in the art and can be produced routinely [*e.g.* refs. 12 to 15] from both human [*e.g.* refs. 16 to 21] and mouse cells.

In step (a), stem cells will typically be grown initially in suspension culture (*e.g.* in a vessel which does not favour cell attachment, such as a petri dish), but during step (a) EBs will generally become non-dispersed and adherent. Techniques such as microbead culture [15] may also be used. A typical starting concentration is around  $5 \times 10^4$  cells per 10ml of culture medium.

If starting stem cells are in adherent culture, they must be disengaged prior to step (a). Standard methods involving the use of enzymatic treatment (*e.g.* with trypsin, papain, collagenase *etc.*), mechanical disaggregation and/or metal ion chelators (*e.g.* EDTA, EGTA *etc.*) *etc.* can be used to disengage the cells.

Taking time zero as the time at which culture conditions are changed to favour EB formation (*e.g.* removal of LIF for murine ES cells), step (a) will generally last between 15 and 60 days, more typically at least 25 days (*e.g.* at least around 28-35 days). Longer periods of culture favour the development of endoderm, from which lung epithelium derives.

Step (a) may be performed in the presence or absence of serum. If serum is not used, a serum replacement may be used instead. The absence of serum avoids the introduction of undefined or random factors which may promote the formation of non-AE2 cell types. Its absence is not essential, however, and a typical medium for use in step (a) is G-MEM supplemented with serum, glutamine, 2-mercaptoethanol and antibiotics. Fresh medium may be supplied during step (a).

In step (b), EBs differentiate into SPC<sup>+</sup> cells. SPC<sup>+</sup> cells may develop with low efficiency in culture using the same medium as used in step (a) *i.e.* when steps (a) and (b) are separate phases of an essentially single continuing culture process. A low inherent differentiation efficiency may be acceptable when other techniques (*e.g.* lineage selection or cell enrichment as described below) are used, but it is preferred to increase differentiation efficiency by subjecting the EBs from step (a) to suitable differentiation conditions *e.g.* exposure to suitable differentiation factors. Such factors will typically be added to the medium in which the EBs are already being cultured or maintained. Alternatively, the EBs may be transferred into a new medium for exposure to the factors, and the new medium may be based on the same or different basal medium as used in step (a). If adherent EBs are to be transferred, they will first be disengaged as described above.

Exposure to 'SAGM' medium has been found to be particularly effective for causing differentiation in step (b). SAGM medium is part of the *Small Airway Epithelial Cell Growth Media System* supplied by Clonetics [22] for the culture of small airway epithelial cells (SAECs). SAGM consists of a serum-free basal medium ('SABM') supplemented with: BPE (bovine pituitary extract), hydrocortisone, hEGF (human recombinant epidermal growth factor), epinephrine, transferrin, insulin, retinoic acid, triiodothyronine, gentamicin, amphotericin-B and BSA-FAF (bovine serum albumin-fatty acid free). The medium generally has a pH in the range 7.4-7.6 and an osmolality of 255-265 mOsm/kg.

Factors which may be used in step (b), either singly or in combinations, are thus: pituitary extracts (e.g. a bovine pituitary extract), steroid hormones (e.g. hydrocortisone, or a salt thereof such as the acetate), growth factors (e.g. epidermal growth factor, preferably human form), catecholamines (e.g. epinephrine, either in racemic or enantiomeric form), iron-binding proteins (e.g. a transferrin), insulin, vitamins (e.g. retinoic acid), thyroid hormones (e.g. triiodothyronine), serum albumins (e.g. bovine or human serum albumin, including recombinant preparations), antibiotics (e.g. aminoglycoside antibiotics, such as gentamicin), and/or antifungals (e.g. amphotericin-B). Optimum sub-combinations of these components can easily be determined by culturing EBs in their presence and assessing the effect on differentiation towards a SPC<sup>+ve</sup> phenotype, as described in the examples below. Other growth factors which may be used include: fibroblast growth factor 1 (FGF 1); FGF 7 (also known as keratocyte growth factor); FGF 10; and hepatocyte growth factor.

Preferred media for use in step (b) include epidermal growth factor. The medium may lack retinoic acid, pituitary extract and/or epinephrine.

It is surprising that SPC<sup>+ve</sup> cells develop in the presence of hydrocortisone as this hormone has previously been reported to suppress SPC gene expression in AE2 cells [23].

As in step (a), cells are preferably grown in serum-free medium in step (b) and, if serum is not used, a serum replacement may be used instead.

Taking time zero as the time at which EBs are exposed to appropriate differentiation factors, step (b) will generally last between 1 and 30 days, and typically at least 3 days (e.g. around 7-14 days).

Cells will usually grow in step (b) in adherent culture. It is preferred to maintain adherent culture for all or substantially all of step (b). A typical starting concentration for step (b) is between 10<sup>4</sup> and 10<sup>5</sup> cells per ml of medium.

The process of the invention produces SPC<sup>+ve</sup> cells from stem cells, via EBs. The cells are described in more detail below. To maintain the SPC<sup>+ve</sup> cells after differentiation from EBs, serum-containing or serum-free media may be used.

Overall, the cells obtained from step (b) may be a heterogeneous population e.g. containing SPC<sup>+ve</sup> cells of the invention, but also containing SPC<sup>-ve</sup> cells. If a more homogenous population is desired,

the product of step (b) can be further treated to remove contaminating cells. Cell enrichment and selection methods are familiar to the skilled person and include the use of flow cytometry (*e.g.* based on AE2-specific markers), of genetic selection, of selective growth media, or of selective killing. In this way, >95% pure cells may be obtained.

- 5 The efficiency of the process of the invention can be measured by comparing the number of SPC<sup>+</sup> cells (output) with the number of stem cells (input). The process is preferably at least 10% efficient (*i.e.* at least 10% of the stem cells differentiate into SPC<sup>+</sup> cells) or higher (*e.g.* 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more). Thus the invention provides a process for differentiating stem cells into SPC<sup>+</sup> cells, wherein the proportion of stem cells which become SPC<sup>+</sup> cells is  $\geq 10\%$
- 10 (*e.g.* 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more).

### ***The starting stem cells***

- The stem cell used in the process of the invention can be any pluripotent or multipotent stem cell. Pluripotent cells have the ability to develop into any cell derived from the three main germ cell layers. Adult stem cells, placental stem cells, fetal stem cells and umbilical stem cells may all be
- 15 used, but preferred stem cells are embryonic stem (ES) cells, embryonic carcinoma (EC) cells or embryonic germ (EG) cells [*e.g.* 24, 25]. Somatic, bone marrow and cord blood stem cells may be used, particularly where autologous AE2 cells are desired.

Methods for obtaining suitable stem cells and for maintaining them (*e.g.* in an undifferentiated state) prior to use in the process of the invention are well known.

- 20 ES cells are cells derived from embryos which can propagate indefinitely in *in vitro* culture. ES cells are pluripotent *i.e.* they have the ability to give rise *in vivo* to all cell types which comprise the adult animal. Murine ES cells [*e.g.* ref. 26] and human ES cells [*e.g.* refs. 27 & 28] are readily available and conditions for their undifferentiated growth are well known [*e.g.* refs. 29 to 39]. ES cells are properly referred to as pluripotent rather than totipotent, as they are incapable of forming some
- 25 non-embryonic cell types.

- In order to ensure compatibility with human patients, human stem cells, and human ES cells in particular, are preferred for use according to the invention. Although it has not yet reached the levels of murine ES cells, knowledge on the growth and differentiation of human ES cells is advanced [*e.g.* refs. 16 & 40-42]. Where non-human patients are to be treated or studied, however, stem cells from
- 30 other organisms (*e.g.* from non-human primates or from mice) may be used. Non-human stem cells may also be used with humans in conjunction with xenotransplantation compatibility techniques.

For administration to humans, it may be preferred to use autologous ES cells. These may be prepared by, for instance, preparing an embryo by somatic cell nuclear transfer from a patient, and deriving ES cells from the embryo. Autologous somatic stem cells may also be used.

Because the provision of large quantities of material for therapeutic use is advantageous, the stem cell is preferably capable of prolonged proliferation *in vitro*.

The stem cell is preferably a human ES cell line which is eligible for US federal funding according to criteria outlined by President Bush in his address of 9th August 2001. More preferably, the stem cell is one which can be obtained from the NIH *Human Embryonic Stem Cell Registry* [43].

### *Artificial alveolar tissue*

The process of the invention produces SPC<sup>+ve</sup> cells from stem cells, via EBs. Thus the invention provides an isolated SPC<sup>+ve</sup> cell differentiated *in vitro* from a stem cell, such as an ES cell.

SPC expression is a characteristic of AE2 cells, but the cells produced according to the invention do not necessarily show all the characteristics of AE2 cells. As well as being SPC<sup>+ve</sup>, it is preferred that the cells produced by the method of the invention have one or more of the following phenotypes: SPA<sup>+ve</sup>; SPB<sup>+ve</sup>; SPD<sup>+ve</sup>; possesses lamellar bodies in the cytoplasm; capable of synthesising and secreting (and preferably recycling) pulmonary surfactant; able to differentiate into AE1 cells; phagocytic; able to proliferate; can bind to AE1 cells; can bind to fibroblasts; cuboidal shape; capable of secreting lysozyme; expresses one or more of alkaline phosphatase, catalase, Na<sup>+</sup>/K<sup>+</sup> ATPase, cytochrome P450 monooxygenase, glycoproteins recognised by *Maclura pomiferae* lectin; stains positive with modified Papanicolaou method, phosphine 3R, tannic acid; and/or capable of regulating hypophase pH and [Ca<sup>2+</sup>]. The cells are most preferably AE2 cells.

These phenotypic properties may be manifested *in vitro* and/or *in vivo*, and it is preferred that they are manifested *in vivo*.

The cells of the invention are preferably murine or human cells.

The cells of the invention are preferably non-tumorigenic. They may have a normal karyotype.

The cells of the invention may be clonal.

Cells of the invention may be in the form of an aggregate or cluster, or in the form of separate cells. Cells in a cluster are preferably present in three dimensions (*i.e.* not as a single layer of cells).

The invention provides a collection of cells, wherein the collection comprises cells of the invention. Within the collection, at least 95% of the total number of cells (*e.g.* at least 96%, 97%, 98%, 99%, 99.5%, 99.9% or more) should be SPC<sup>+ve</sup> cells of the invention (*e.g.* 100%). Thus the invention provides a collection of cells which are entirely SPC<sup>+ve</sup> cells. Previous methods of purifying AE2 cells from lung tissue [*e.g.* refs. 6 to 10] do not achieve more than about 95% purity.

The cells in the collection are preferably of a single genotype or haplotype.

The collection or cluster preferably lacks undifferentiated starting stem cells.

The collection or cluster preferably lacks epithelial cell types, fibroblasts and/or endothelial cells (*e.g.* vasculature).

The collection preferably includes at least 1000 SPC<sup>+ve</sup> cells.

5 The invention provides a collection of cells, wherein the collection comprises SPC<sup>+ve</sup> cells, and wherein the number of said SPC<sup>+ve</sup> cells per gram weight of all cells in the collection is at least 10<sup>8</sup> (*e.g.* at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup> *etc.*).

A collection of cells may additionally include AE1 cells and/or mesenchyme. A preferred collection of cells comprises AE2 cells, AE1 cells, vasculature and supporting matrices, arranged substantially identically to natural lung tissue.

10 The cells, collections and clusters of the invention may be located *in vitro* or *in vivo*. When *in vitro*, they may be in isolated form.

The cells, and collections and clusters thereof, are useful for pulmonary therapy and for *in vitro* studies of alveolar function.

15 The invention provides lung tissue comprising a cell of the invention. In particular, the invention provides comprising lung tissue comprising a cell of the invention at an alveolar surface thereof.

The invention provides a cell culture comprising SPC<sup>+ve</sup> cells, wherein the mass of said cells within the culture is at least 10 grams (*e.g.* 20, 50, 100, 500, 1000, 2000, 10000 g).

20 The invention provides a cell culture comprising SPC<sup>+ve</sup> cells, wherein the proportion of said SPC<sup>+ve</sup> cells compared to the total number of cells in the medium is 95% or greater (*e.g.* 96%, 97%, 98%, 99%, 99.5%, 99.9% or more).

The invention provides an isolated SPC<sup>+ve</sup> cell, wherein the telomeres in the cell are longer than the telomeres in a SPC<sup>+ve</sup> cell found *in vivo* in lung tissue of the same species.

### ***Therapeutic methods***

25 Cells of the invention are suitable for inducing lung tissue regeneration *in vivo*. Thus the invention provides a method of treating a patient, comprising administering cells of the invention to the patient.

The invention also provides the cells of the invention for use as a medicament.

The invention also provides the use of the cells of the invention in the manufacture of a medicament for treating a patient.

30 For therapy, the cells are preferably in the form of single cells, rather than a cluster or a collection of cells of the invention.

The invention also provides a syringe containing cells of the invention.

Cells of the invention may be encapsulated *e.g.* in an alginate hydrogel [44] or in any other biodegradable and biocompatible material (*e.g.* poly(lactide-co-glycolide) 'PLG'). The encapsulated cells may include appropriate soluble factors *e.g.* for promoting engraftment in the lung, or for repressing differentiation of AE2 cells to AE1 cells (see below) prior to engraftment.

- 5 Cells are preferably administered to the distal lung of a patient. They may be administered direct to the distal lung, or they may be delivered remotely, after which the cells are transported to the lung where they 'dock'.

Cells of the invention are also suitable for inducing lung tissue regeneration *ex vivo*, for instance in tissue prior to transplant. Thus the invention provides an *ex vivo* method for modifying lung tissue,  
10 comprising adding a cell of the invention to said lung, preferably to an alveolar surface.

The number of cells to be delivered *in vivo* or *ex vivo* is based on a number of parameters, including: the body weight of the recipient, the severity of disease, and the number of cells surviving within the subject. A typical number of cells may be around  $10^7$  to  $10^8$  cells per kg body weight. It may be necessary to repeat infusions of the cells over several months to achieve the necessary cumulative  
15 total mass and/or to replace cells which are dying.

The cells will be delivered in combination with a pharmaceutical carrier. This carrier may comprise a cell culture medium which supports their viability. The medium will generally be serum-free in order to avoid provoking an immune response in the recipient. The carrier will generally be buffered and/or pyrogen-free.

- 20 Procedures for the preparation of cells of the invention for transplantation into a subject may include methods of protecting cells against an inflammatory response by the transplant recipient. For instance, the cells of the invention may be co-administered with anti-inflammatory agent(s). The cells may be delivered in conjunction with an anticoagulant (*e.g.* heparin) and/or with human serum albumin (preferably recombinant), typically in the same injection. Encapsulation may also be used,  
25 as described above.

The cells of the invention are preferably matched (*e.g.* by HLA-typing) to the recipient patient in order to avoid rejection. This can conveniently be achieved by preparing the cells from stem cells which are compatible with the recipient. For example, the stem cells could be derived from the recipient *e.g.* adult stem cells, or autologous ES cells prepared as described above. If cells are not  
30 well matched, they may be administered together with an appropriate immunosuppressant.

Included within the invention are methods and uses in which immature cells are transplanted into a recipient, where they subsequently mature into cells of the invention. Unlike the mature cells, the immature cells may not themselves be SPC<sup>+</sup> cells, although they will become so *in vivo*.



***In vitro investigative methods***

The cells of the invention are essentially artificial alveolar tissue, although they do not necessarily exhibit all the characteristics of alveoli. Because of their ability to secrete SPC (and, indeed, other components of pulmonary surfactant), the cells can be used instead of alveolar tissue in *in vitro* screening assays. Cells of the invention are thus suitable for *in vitro* studies of alveolar tissue.

The invention provides an *in vitro* assay (e.g. for assessing the effect(s) of a test substance on alveolar pneumocytes), comprising the steps of (a) incubating a test substance with cells of the invention, and (b) detecting changes in said cells.

The substance may be a single compound or a mixture of compounds. Typically, it will be a pollutant (e.g. occupational or environmental) or a toxin. Components of cigarette smoke may be used.

Step (b) involves comparing cells after treatment with the substance to starting cells, with changes being caused by exposure to the substance. Various methods may be used for detecting the changes. At one extreme, detection of cell death (e.g. by necrosis, lysis, apoptosis *etc.*) is easily detected. Where cell death does not occur, other changes may be detected, such as: changes in morphology e.g. detected by microscope; changes in gene expression e.g. detected by Northern blotting, by SAGE, by microarray profiling *etc.*; changes in changes in protein expression e.g. detected by Western blotting, by immunoassay, by 2D-PAGE *etc.*; changes in genetic structure e.g. detected by standard genotoxicity assays; *etc.* The change may be one or more of the following: secretion of pulmonary surfactant; up-regulation of SPA, SPB, SPC and/or SPD transcription and/or translation; or cell proliferation and/or differentiation. The change may be monitored directly or indirectly.

The changes in step (b) may also be used to provide information on the etiology of pulmonary disease in the alveolar region of the lung.

Cells of the invention may also be used for investigating mechanisms of lung repair and/or regeneration. For instance, known pulmonary toxins could be administered to cells of the invention and then test substances could be assayed for their ability to ameliorate the toxicity.

Cells are also useful for screening for pharmacologically active substances. In such cases typical test substances are compounds which include, but are not restricted to, peptides, peptoids, proteins, lipids, metals, nucleotides, nucleosides, small organic molecules, antibiotics, polyamines, and combinations and derivatives thereof. Small organic molecules have a molecular weight of more than 50 and less than about 2,500 Da, and most preferably between about 300 and about 800 Da. Complex mixtures of substances, such as extracts containing natural products, or the products of mixed combinatorial syntheses, can also be tested and the component that causes secretion can be purified from the mixture in a subsequent step.

Test substances may be derived from large libraries of synthetic or natural compounds. For instance, synthetic compound libraries are commercially available from Maybridge Chemical Co. or Aldrich.

Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts may be used. Additionally, test compounds may be synthetically produced using combinatorial chemistry either as individual compounds or as mixtures.

5 The screening method may be in a high-throughput format. Preferably, all the biochemical steps for this assay are performed in a single solution in, for instance, a test tube or microtitre plate, and the test compounds are analysed initially at a single compound concentration. for the purposes of high throughput screening, the experimental conditions are adjusted to achieve a proportion of test compounds identified as "positive" compounds from amongst the total compounds screened. The assay is preferably set to identify compounds with an appreciable affinity towards the target *e.g.*,  
10 when 0.1% to 1% of the total test compounds from a large compound library are shown to bind to a given target with a  $K_i$  of 10 $\mu$ M or less (*e.g.* 1 $\mu$ M, 100nM, 10nM, or less)

The invention also provides a compound identified by the method of the invention, optionally in combination with a pharmaceutical carrier. The compounds may themselves be useful pharmaceuticals or they may be useful lead compounds for development into pharmaceuticals. They  
15 are preferably organic compounds. The invention provides a compound identified by the method of the invention for use as a medicament, and the use of a compound identified by the method of the invention in the manufacture of a medicament for treating alveolar dysfunction.

### ***AE1 cells***

AE2 cells can proliferate and can differentiate into AE1 cells [5]. Thus the invention provides a  
20 method for preparing an AE1 cell, comprising the step of culturing a cell of the invention under appropriate conditions. The process preferable occurs *in vitro*.

### ***Genetic manipulation of cells***

A stem cell may have been genetically manipulated prior to use in the process of the invention. Similarly, differentiated derivatives of the stem cells may be genetically manipulated after the  
25 process of the invention has been performed. This may involve activation or over-expression of endogenous genes and/or introduction of exogenous genes.

Suicide genes A cell may have been genetically manipulated to include a "suicide gene". This provides a method of selectively killing cells which may persist in cell preparations to be administered to patients (*e.g.* undifferentiated stem cells), or all cells (differentiated or  
30 undifferentiated) derived from the stem cells as a failsafe mechanism to destroy the cells after transplantation. Suicide genes encode protein products that have no appreciable direct effect on cellular function, but which are capable of conferring toxicity by their ability to convert otherwise non-toxic substances (frequently termed prodrugs) into toxic metabolites. Suicide gene technology has been developed as a means of rendering cancer cells more sensitive to chemotherapeutics and  
35 also as a safety feature of retroviral gene therapy. Several combinations of suicide genes and prodrugs are known in the art [*e.g.* ref. 45] and include: *E.coli* cytosine deaminase +

5-fluorocytosine; HSV thymidine kinase + ganciclovir or acyclovir; *E.coli* nitroreductase + CB1954 *etc.* The suicide gene is preferably under the control of a promoter expressed in undifferentiated stem cells or in other cells undesirable for transplantation (*e.g.* tumors or tumorigenic cells), in which case undifferentiated cells can be removed from culture by using the appropriate prodrug without affecting differentiated cells. For use as a failsafe mechanism to allow selective killing of a transplant in a patient (*e.g.* where the transplant is found to be harmful in a recipient), however, the suicide gene will generally be under the control of a constitutive promoter, although tissue-specific or inducible promoters may be used.

Differentiation promotion A stem cell may have been genetically manipulated to encode a polypeptide (*e.g.* a transcription factor) which promotes differentiation of the stem cell into a SPC<sup>+</sup> cell in step (a) or step (b). The same strategy may be used to maintain and/or stabilise a SPC<sup>+</sup> phenotype. Expression of this polypeptide may be controlled so that it occurs in the stem cell itself, or so that it occurs in a derivative of the stem cell (*e.g.* in EBs). Conversely, a cell may have been genetically manipulated such that it under-expresses or does not express a polypeptide (*e.g.* a transcription factor) which either favours differentiation of the stem cell away from a SPC<sup>+</sup> phenotype or which inhibits differentiation into a SPC<sup>+</sup> cell. For instance, genes could be knocked out, or could be inhibited using antisense or RNA silencing (*e.g.* RNAi [*e.g.* refs. 46-49]) techniques.

Lineage selection and enrichment A cell may have been genetically manipulated to insert markers suitable for lineage selection, a technique which specifically selects a desired cell type *e.g.* based on a previously-inserted recombinant construct which comprises a tissue-specific promoter linked to a selectable marker. Where the efficiency of differentiation of stem cells into cells of the invention is inherently low, this technique allows efficiency to be increased. Suitable selectable marker genes include, but are not restricted to, drug selectable genes (*e.g.* the G418 resistance gene, zeo, bsd, HPRT, hygromycin, puromycin), visible markers such as fluorescent proteins (*e.g.* GFP, DsRed) and genes which facilitate selection by automated cell sorting (*e.g.* genes encoding cell surface antigens).

A cell may have been genetically manipulated to insert markers suitable for enrichment of cells from within a heterogeneous population. One possibility is to place a marker protein under the control of an AE2-specific promoter (*e.g.* the SPC promoter) such that the marker is transcribed in parallel to natural AE2-specific genes. The marker can then be detected and used for enriching cells of the invention (*e.g.* by FACS).

Compatibility A cell may have been genetically manipulated so that expression of reactive antigens is reduced or eliminated. For instance, genes which encode auto-antigens could be knocked out, or they could be inhibited using antisense techniques or RNA silencing (*e.g.* RNAi).

The genetic manipulations described above may be used singly, or two or more may be used in combination.

Genetic manipulation of the cell may occur through random integration into the genome or by gene targeting. As an alternative the manipulation may, where appropriate, use an episomally-maintained vector (e.g. a plasmid). Transfection of ES cells, including human ES cells [21], is well known.

For random integration, vector(s) which encode the relevant polypeptides may be introduced into the cell. Typically, an expression vector comprising a gene promoter operably linked to DNA encoding the relevant polypeptide would be used. The coding DNA may be cDNA, genomic sequences or a mixture of both. The promoter may direct constitutive or inducible expression and may be tissue-specific. Examples of constitutive promoters include the promoters from  $\beta$ -actin, phosphoglycerate kinase (PGK), glycolytic enzymes, elongation factor 1 $\alpha$  (EF1 $\alpha$ ), or SV40. Examples of inducible gene promoters include systems composed of a chimeric transactivator that reversibly binds to the promoter region of the expression construct in response to a drug or ligand (e.g. doxycycline, ecdysone, mifepristone, tetracycline, FK1012, or rapamycin).

An alternative to random integration is the precise alteration of genes *in situ* by homologous recombination, termed "gene targeting". This is the precise predetermined modification of genes by homologous recombination between exogenous and endogenous DNA. Gene targeting can be used to insert, replace, rearrange or remove chosen DNA sequences in cultured cells, most commonly embryonic stem cells [e.g. ref. 50]. In some circumstances gene targeting may be preferable to simple introduction of an expression vector at a random site because the genetic modification can be predetermined to avoid any deleterious effect (e.g. oncogenic transformation) that would reduce the therapeutic value of derived cells.

Gene targeting may be used to achieve constitutive or inducible expression of a gene of interest by modifying or replacing the natural promoter or other regulatory regions of that gene. For example, a gene promoter may be replaced with a constitutive or inducible promoter or elements which direct constitutive expression may be added adjacent to the endogenous gene promoter. Methods to achieve such modifications by gene targeting, including in ES cells, are well known in the art.

It is also possible to perform genetic manipulation on a cell other than a stem cell, and then to transfer that genetic manipulation into a stem cell (e.g. by transfer of a nucleus into an enucleated stem cell) or into an embryo (e.g. by transfer of a nucleus into an enucleated oocyte) which can give rise to a stem cell. Both of these approaches indirectly give a genetically-manipulated stem cell.

#### Alternative step (a)

As an alternative to forming EBs in step (a), the stem cells may be co-cultured with lung mesenchyme. Embryonic lung mesenchyme is particularly suitable.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1 and 2 show phase contrast microscopy of differentiating ES cells at confluence after trypsinization and subculture in (1) ES cell medium or (2) SAGM medium. The bar is 500 $\mu$ m.

Figure 3 shows PCR amplification of  $\beta$ -actin gene in a single sample with increasing cycle numbers.

Figures 4 to 6 show RT-PCR results for cells differentiated through EBs. Figure 4 shows the results of a first PCR amplification, with figure 5 showing the results of a second nested amplification. Figure 6 shows the presence of  $\beta$ -actin.

5 Figure 7 shows the results of *StuI* digestion of the PCR products from Figures 4 to 5.

Figures 8 to 10 show the results of RT-PCR for cells differentiated without EB formation. The figures parallel figures 4 to 6.

Figure 11 is a high power photomicrograph showing an ES cell-derived cell cluster grown in SAGM, immunostained for SPC (bar = 80  $\mu$ m).

10 Figure 12 is an electron micrograph of a cytoplasmic organelle within such a cluster, with the characteristic structure of a AE2 lamellar body visible (bar = 100 nm).

## MODES FOR CARRYING OUT THE INVENTION

### *Culture and differentiation of ES cells*

15 Murine E14Tg2a ES cells [51; Dr A. Smith, University of Edinburgh, Scotland] were grown in an undifferentiated state on gelatin-coated tissue culture plates in the presence of 1000 U/ml LIF. Cells were maintained in 'ES cell medium' [Glasgow Minimum Essential Medium (G-MEM; available as catalogue number 11710 or 22100 from *Invitrogen Life Technologies*) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, and antibiotics (penicillin 100U/ml; streptomycin 100 $\mu$ g/ml); no tryptose broth].

20 To promote AE2 cell formation, ES cells were first induced to differentiate spontaneously in ES cell medium via EB formation. For this, confluent cultures of undifferentiated ES cells were subjected to limited trypsin digestion (0.05% trypsin; 0.53 mM EDTA in 0.1 M PBS without calcium or magnesium; 2% chicken serum) to produce clusters of 8-15 cells, which were cultured in non-adherent bacterial grade Petri dishes in ES cell medium without LIF (day 0). Most EBs adhered  
25 to the dish surface after 8-10 days of culture and the cells spread out. The differentiating ES cells were fed on alternate days with ES cell medium for periods of 10-, 20- or 30-days. At the end of each time period, cells were either maintained in ES cell medium or were transferred into 'SAGM' medium (Biowhittaker, Watersville, MD) designed for the growth and maintenance of mature distal lung epithelium, at an initial cell seeding density of  $5 \times 10^4$  cells/cm<sup>2</sup>. SAGM consists of basal  
30 medium plus the following factors: 0.5 mg/ml bovine serum albumin, 5  $\mu$ g/ml insulin, 10  $\mu$ g/ml transferrin, 30  $\mu$ g/ml bovine pituitary extract, 0.5  $\mu$ g/ml epinephrine, 6.5 ng/ml triiodothyronin, 0.1 ng/ml retinoic acid, 0.5  $\mu$ g/ml hydrocortisone, 0.5 ng/ml human epidermal growth factor and antibiotics (gentamycin sulphate 0.05 mg/ml; amphotericin-B 0.05mg/ml). Following incubation for 3 or 14 days, as arbitrary short and long growth intervals, cells were collected for analyses.

In parallel experiments, ES cells were induced to differentiate by LIF removal alone without formation of EBs. This process encourages accumulation of primitive endoderm-like cells on the outside of undisrupted ES cell colonies. Cells were passaged continually several times (from passage number 13 through to 20) before being maintained in ES cell medium or transferred to SAGM and sampled as for EB-derived cultures.

Undifferentiated ES cells grew in tightly packed colonies. Routine daily examination revealed changes in the appearance of the cultures following induction of spontaneous differentiation, regardless of the route used *i.e.* whether via EB formation or LIF removal alone. In outgrowths of cells from each adherent EB, it was possible to see differentiation into a variety of cell types, including epithelial cells and twitching muscle cells. However, following trypsinization and subsequent culture in the same medium (ES cell medium), the cells appeared to be organized into two areas with distinct morphologies – small round cells with a large nucleus-to-cytoplasm ratio arranged in groups or islands, and others with fibroblastic appearance filling the spaces between groups of small cells (Figure 1). Transfer into SAGM caused a reduction in the number of small groups of cells, presumably due to cell death, and resulted in the spaces between the groups being filled with fewer and more flattened cells (Figure 2).

During culture, cells were examined daily under an inverted light microscope. At the end of each period of culture in the two different media, cells were sampled in order to detect type II pneumocytes by:

- a) reverse transcriptase-polymerase chain reaction (RT-PCR) for SPC mRNA, a specific marker for this cell type,
- b) immunocytochemistry for SPC and
- c) transmission electron microscopy (TEM) for detection of lamellar bodies, which are the sites of surfactant protein storage and are thus characteristic of AE2 cells.

#### ***SPC mRNA expression***

RT-PCR was carried out on RNA extracted from differentiating ES cells cultured in ES cell medium or SAGM after 10-, 20- and 30-days of differentiation and growth in ES cell medium. Total RNA was extracted from the cultured cells using TRIzol reagent (Life Technologies) following the manufacturer's instructions. Thermoscript RT-PCR System (Life Technologies) was used to synthesize cDNA from 1 µg total RNA. Oligo(dT)<sub>20</sub> was used to prime RT reactions which enabled the same cDNA to be PCR amplified with different sets of gene-specific primers. 1 µl cDNA samples (5% of RT reaction) were amplified with primers selective for murine SPC and β-actin using the hot start enzyme Gold DNA polymerase (PE Applied Biosystems Inc). To ensure that only cDNA and not any potential contaminating genomic DNA was amplified, SPC PCR primers were designed to separate exons or to anneal across exon/exon boundaries. Primer sequences and the amplicon length are given in the following table:

Amplified sequence	Name	Description	SEQ ID	Amplicon length (bp)
SPC	SPC1	Forward primer on exon 3/4	1	295 <sup>a</sup>
	SPC2	Forward primer on exon 4	2	252 <sup>a</sup>
	SPC3	Reverse primer on exons 6/5	3	-
$\beta$ -actin	$\beta$ 1	Forward primer	4	495 <sup>b</sup>
	$\beta$ 2	Reverse primer	5	-

<sup>a</sup> length when used in conjunction with SPC3

<sup>b</sup> length when used in conjunction with  $\beta$ 2

In the 30  $\mu$ l PCR reaction mix, the final concentrations of MgCl<sub>2</sub> and dNTPs were 2.5 mM and 0.1 mM, respectively. DNA amplification was performed in a Perkin Elmer GeneAmp PCR System 2400. Double-stranded DNA denaturation and the activation of AmpliTaq Gold DNA Polymerase was carried out at 94°C for 10 minutes, followed by 35 cycles of: template denaturation at 94°C (5 s), primer annealing at 56°C (10 s) and primer extension at 72°C (30 s). 1  $\mu$ l of PCR reaction mix was amplified for further 15 cycles in a nested PCR reaction. A period of 7 minutes post-PCR extension at 72°C was carried out for both PCR reactions. PCR products were separated on 2% agarose gel and visualised by ethidium bromide fluorescence.

Figure 4 shows the SPC amplicons after 35 cycles of PCR from cDNA synthesized from the equivalent of 50 ng of total RNA in cells initially cultured in ES cell medium for 30 days. Cells cultured in ES cell medium are shown in lanes 1 and 2 (3 and 14 days culture in ES cell medium, respectively). Cells cultured in SAGM are shown in lanes 3 and 4 (3 and 14 days culture). Lane 5 is a positive control amplified from adult murine lung cDNA. Weak bands are visible in lanes 3 and 4, but no bands were visible in cells grown only in ES cell medium. Therefore only SAGM-treated cells expressed SPC.

SPC expression was further studied by nested PCR for an additional 15 cycles. Results are shown in Figure 5, with the lanes being the same as in Figure 4. SPC amplicons are visible in cells grown solely in ES cell medium, but at a much lower level than for cells cultured in SAGM (lanes 3 and 4).

The nested PCR results confirmed the specificity of the SPC amplicon, and specificity was further verified by analysis of *Stu*I restriction enzyme digests. As expected, *Stu*I cut once to give products of 224 bp + 71 bp and 181 bp + 71 bp for the SPC and nested amplicons, respectively (Figure 5).

To determine non-saturating PCR conditions for  $\beta$ -actin, the gene was amplified for 19, 22, 25, 28 & 31 cycles in triplicate using RT-material from a single sample first. Digital images of ethidium bromide-stained gels were captured using the Bio-Rad *Fluor-S MultiImager* system, which consists of an enclosed flat-bed UV light scanner and CCD camera, connected to a computer. Images were analyzed using Bio-Rad *Quantity One* quantitation software, which allows detection of the individual bands and subtraction of background noise, yielding intensity values due solely to the gene-specific amplified products. The linear range of PCR amplification was best after 22 cycles (Figure 3). PCR

was thus performed for 22 cycles on all cDNA samples, and revealed similar levels of the housekeeping gene,  $\beta$ -actin, for all four treatments (Figure 6). The mean sample fluorescent intensities were  $486 \pm 27$ ,  $448 \pm 30$ ,  $462 \pm 19$ ,  $483 \pm 78$  (SEM; N=3) (Figure 6, lanes 1-4).

For cells initially cultured in ES cell medium for 10 or 20 days and then transferred to SAGM, bands could not be detected either with 35 cycles of amplification or with nested PCR.

For cells which did not progress through EBs, SPC amplicons were not detected. Figure 9 shows the lack of amplicon after 35 cycles of PCR, and Figure 10 shows the same lack after additional nested PCR. Lane 1 shows cells cultured in ES cell medium after LIF removal and lane 2 shows cells cultured in SAGM after LIF removal. Lane 3 is a positive control (adult murine lung cDNA). Figure 11 shows that  $\beta$ -actin cDNA was present in all samples.

Control reactions in which reverse transcriptase was omitted from the RT step were negative.

Therefore optimum conditions for producing SPC<sup>+</sup> cells involve: (a) differentiation via EBs; (b) more than 20 days of culture, and preferably at least 30 days, for producing the EBs; (b) transfer of the EBs into SAGM medium followed by culture for more than 3 days.

### ***SPC protein expression***

Cells grown in multi-chamber slides were rinsed twice in phosphate-buffered saline and fixed in 4% paraformaldehyde at room temperature for 30 minutes. Immunofluorescence staining of cultured cells was carried out using rabbit polyclonal antibodies to SPC (Chemicon, Temecula, CA; overnight incubation at dilution 1:200). The second layer comprised FITC-conjugated goat anti-rabbit IgG (dilution 1:200; Sigma). Preparations were viewed under an Olympus BX-60 microscope.

Scattered immunoreactive cells, single or in clusters, were seen in cultures grown in either ES cell medium or SAGM. Figure 11 shows a cell grown in SAGM (bar = 80 $\mu$ m).

Variability in the quality of the immunostaining and the clumping of cells precluded any quantitative analysis.

### ***Cellular ultrastructure***

Further confirmation of alveolar type epithelial differentiation came from cellular ultrastructure studies. Cells were rinsed twice in phosphate-buffered saline and fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer pH 7.25 for 25 minutes, washed three times in 0.1 M phosphate buffer with 0.1M sucrose and post fixed in 1% osmium tetroxide in 0.1 M phosphate buffer. Following two washes in the phosphate buffer with sucrose, the cells were scraped from the wells, transferred to microfuge tubes and centrifuged. Pellets were dehydrated through a graded series of alcohols, followed by propylene oxide and embedded in Araldite resin. Ultra-thin sections of silver-gold interference colour were stained with 4% uranyl acetate in methanol and observed in a Zeiss 10 CR electron microscope.



Figure 12 (bar = 100nm) shows that cells include osmiophilic lamellar bodies composed of AE2-typical concentric laminae after growth in SAGM. In addition, extrusion of tubular myelin could sometimes be seen.

### ***SAGM dissection***

- 5 SAGM consists of a serum-free basal medium supplemented with: BPE, hydrocortisone (HC), hEGF, epinephrine (EPi), transferrin, insulin, retinoic acid (RA), triiodothyronine (T3), gentamicin, amphotericin-B and BSA-FAF. Six of these components were removed singly from SAGM and the effect on AE2 derivation was assessed by quantitative PCR of SPC mRNA (Figure 13).

- 10 Compared with basic medium (GMEM + 10% fetal calf serum), SAGM showed a >100% increase in SPC mRNA. Removal of most SAGM components increased SPC mRNA levels *i.e.* these factors have suppressive effects on SPC expression. Removal of hEGF, however, reduced SPC levels, suggesting that this growth factor stimulates SPC expression. SAGM minus the suppressive factors is a preferred medium.

- 15 In a later experiment, ES cells were grown in basic medium for 10 days and then kept either in the basic medium or transferred to (i) complete SAGM; (ii) SAGM minus HC; or (iii) SAGM minus RA. No SPC mRNA was detected in cells grown in basic medium or complete SAGM, but it was found in cells grown in modified SAGM, indicating differentiation to give AE2 cells.

It will be understood that the invention has been described above by way of example only and that modifications may be made whilst remaining within the scope and spirit of the invention.

**REFERENCES** (the contents of which are hereby incorporated in full)

- [1] Wright *et al.* (1984) pages 1068-1074 of *The Biology of Epithelial Cell Populations* (OUP).
- [2] Solarin *et al.* (2001) *Pediatr Pathol Mol Med* 20:471-500.
- [3] Johansson (1998) *Biochim Biophys Acta* 1408:161-172.
- [4] Beers & Fisher (1992) *Am J Physiol* 263:L151-160.
- [5] Fehrenbach (2001) *Respir. Res.* 2:33-46.
- [6] Castranova *et al.* (1988) *Toxicol Appl Pharmacol* 93:472-483.
- [7] Dobbs *et al.* (1986) *Am Rev Respir Dis* 134:141-145.
- [8] Jassal *et al.* (1991) *In Vitro Cell Dev Biol* 27A:625-632.
- [9] International patent application WO01/42425.
- [10] Corti *et al.* (1996) *Am. J. Respir. Cell Mol. Biol.* 14:309-315.
- [11] Shannon *et al.* (1999) *Development* 126:1675ff.
- [12] Desbaillets *et al.* (2000) *Exp Physiol* 85:645-51.
- [13] Keller (1995) *Curr Opin Cell Biol* 7:862-9.
- [14] Mueller-Klieser (1997) *Am J Physiol* 273:C1109-23.
- [15] Magyar *et al.* (2001) *Ann N Y Acad Sci* 944:135-43.
- [16] Zhang *et al.* (2001) *Nature Biotechnol* 19:1129-33.
- [17] Schuldiner *et al.* (2000) *PNAS USA* 97:11307-11312.
- [18] Carpenter *et al.* (2001) *Exp Neurol* 172(2):383-397.
- [19] Schuldiner *et al.* (2001) *Brain Res* 913(2):201-205.
- [20] Kehat *et al.* (2001) *J Clin Invest* 108(3):407-414.
- [21] Eiges *et al.* (2001) *Curr Biol* 11:514-518.
- [22] See [www.cambrex.com](http://www.cambrex.com).
- [23] Shannon *et al.* (2001) *Am J Respir Cell Mol Biol* 24:235-244.
- [24] US patent 6,090,622.
- [25] Donovan & Gearhart (2001) *Nature* 414:92-97.
- [26] US patent 5,670,372.
- [27] US patent 6,200,806.



- [28] Thomson *et al.* (1998) *Science* 282, 1145-7.
- [29] Smith (2001) *Ann. Rev Cell Dev Biol* 17:435-62.
- [30] National Institutes of Health, Dept of Health and Human Services Report. *Stem cells: scientific progress and future research directions*. June 2001 ([www.nih.gov/news/stemcell/scireport.htm](http://www.nih.gov/news/stemcell/scireport.htm)).
- [31] Robertson (1987) *Teratocarcinomas and embryonic stem cells, a practical approach*. IRL Press.
- [32] Wobus (2001) *Mol Aspects Med* 22:149-64.
- [33] Tessarollo (2001) *Methods Mol Biol* 158:47-63.
- [34] Wobus *et al.* (2001) *Methods Mol Biol* 158:263-86.
- [35] Marshall *et al.* (2001) *Methods Mol Biol* 158:11-18.
- [36] Wobus *et al.* (2000) *Cells Tissues Organs* 166:1-5.
- [37] Pera *et al.* (2000) *J Cell Sci* 113:5-10.
- [38] Lebkowski *et al.* (2001) *Cancer J 7 Suppl* 2:S83-93.
- [39] *Embryonic Stem Cells: Methods and Protocols* (ed. Turksen) 2002. ISBN 0896038815.
- [40] Zhang *et al.* (2001) *Nature Biotechnol.* 19:1129-1133.
- [41] Donovan *et al.* (2001) *Nature* 414:92-97.
- [42] Pera (2001) *Curr Opin Genet Dev.* 11:595-599.
- [43] <http://escr.nih.gov/>
- [44] Siebers *et al.* (1997) *Ann N Y Acad Sci* 831:304-12.
- [45] Springer & Niculescu-Duvaz (2000) *J Clin Invest* 105:1161-1167.
- [46] Zamore (2001) *Nat Struct Biol* 8:746-750.
- [47] Carthew (2001) *Curr Opin Cell Biol* 13:244-248.
- [48] Billy *et al.* (2001) *PNAS USA* 98:14428-14433.
- [49] Yang *et al.* (2001) *Mol Cell Biol* 21:7807-7816.
- [50] Ledermann (2000) *Exp Physiol* 85:603-613.
- [51] Hooper *et al.* (1987) *Nature* 326:292.

**CLAIMS**




1. A process for causing a stem cell to differentiate into a cell which expresses surfactant protein C (SPC), the process comprising the steps of: (a) culturing the stem cell to give an embryoid body; and (b) culturing the embryoid body under conditions which cause it to differentiate into cells which express surfactant protein C.
2. The process of claim 1, wherein stem cells are grown initially in step (a) in suspension culture.
3. The process of claim 1 or claim 2, wherein embryoid bodies formed in step (a) are exposed to differentiation factors.
4. The process of any preceding claim, wherein step (b) takes place in the presence of epidermal growth factor.
5. The process of any preceding claim, wherein step (b) takes place in the presence of SAGM.
6. The process of any preceding claim, wherein the stem cell is an embryonic stem (ES) cell.
7. A SPC<sup>+</sup> cell differentiated *in vitro* from a stem cell.
8. A collection comprising a plurality of cells, wherein at least 95% of the total number are SPC<sup>+</sup>.
9. A cell culture comprising SPC<sup>+</sup> cells, wherein the mass of said cells within the culture is at least 10 grams.
10. An isolated SPC<sup>+</sup> cell, wherein the telomeres in the cell are longer than the telomeres in a SPC<sup>+</sup> cell found *in vivo* in lung tissue of the same species.
11. An ES-derived cell, in which SPC is expressed.
12. A method of treating a patient, comprising administering cells according to any one of claims 7 to 11 to the patient.
13. Cells according to any one of claims 7 to 11 for use as a medicament.
14. Use of cells according to any one of claims 7 to 11 in the manufacture of a medicament for treating a patient.
15. A syringe containing cells according to any one of claims 7 to 11.
16. Cells according to any one of claims 7 to 11, wherein the cells are encapsulated in an artificial material.

17. A collection of cells, wherein the collection comprises SPC<sup>+</sup> cells, and wherein the number of said SPC<sup>+</sup> cells per gram weight of all cells in the collection is at least 10<sup>9</sup>.
18. An *in vitro* assay comprising the steps of (a) incubating a test substance with cells according to any one of claims 7 to 11, and (b) detecting changes in said cells.
- 5 19. A method for preparing an AE1 cell, comprising the step of culturing cells according to any one of claims 7 to 11 under appropriate conditions.
20. A process for differentiating stem cells into SPC<sup>+</sup> cells, wherein the proportion of stem cells which become SPC<sup>+</sup> cells is more than 50%.
- 10 21. A process for causing a stem cell to differentiate into a cell which expresses surfactant protein C, the process comprising the steps of: (a) co-culturing the stem cell with lung mesenchyme; and (b) culturing the cell under conditions which cause it to differentiate into a cell which expresses surfactant protein C.


1/4

**FIGURE 1****FIGURE 2****FIGURE 3**


2/4

**FIGURE 4****FIGURE 5****FIGURE 6**


**FIGURE 7**




**FIGURE 8**






**FIGURE 9**



**FIGURE 10**





**FIGURE 11****FIGURE 12****FIGURE 13**

## SEQUENCE LISTING

**SEQ ID 1:**TAT GAC TAC CAG CGG CTC CT**SEQ ID 2:**

5 GAA CCT ACT GCT ACA TCA TGAAGA TG

**SEQ ID 3:**GTT TCT ACC GAC CCT GTG GA**SEQ ID 4:**

GTC GTA CCA CAG GCA TTG TGA TGG

10 **SEQ ID 5:**

GCA ATG CCT GGG TAC ATG GTG G

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number  
**WO 2004/015091 A3**

(51) International Patent Classification<sup>7</sup>: C12N 5/06, 5/08,  
A61K 35/42, A61P 11/00

(74) Agents: MARSHALL, Cameron, John et al.; Carpmals  
& Ransford, 43 Bloomsbury Square, London WC1A 2RA  
(GB).

(21) International Application Number:  
PCT/GB2003/003407

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0218332.5 7 August 2002 (07.08.2002) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): NO-  
VATHERA LIMITED [GB/GB]; 90 Fetter Lane, London  
EC4A 1JP (GB).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BISHOP, Anne,  
Elizabeth [GB/GB]; Tissue Engineering & Regenerative  
Medicine Centre, Faculty of Medicine - Imperial College  
London, Chelsea & Westminster Hospital, Fulham Road,  
London SW10 9NH (GB). POLAK, Julia, Margaret  
[GB/GB]; Tissue Engineering & Regenerative Medicine  
Centre, Faculty of Medicine - Imperial College London,  
Chelsea & Westminster Hospital, Fulham Road, London  
SW10 9NH (GB).

(88) Date of publication of the international search report:  
8 April 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: PREPARATION OF TYPE II PNEUMOCYTES FROM STEM CELLS

(57) Abstract: Stem cells are induced in culture to form cells which express surfactant protein C (SPC), thereby offering a convenient and abundant supply of alveolar tissue without requiring lung donation or the use of cadavers. Stem cells are cultured to give embryoid bodies, which are then maintained under conditions which cause them to differentiate into cells which express SPC. SAGM medium has been found to be particularly effective for causing differentiation of the embryoid bodies.

WO 2004/015091 A3

# INTERNATIONAL SEARCH REPORT

Intern      Application No  
PCT/GB 03/03407

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7    C12N5/06    C12N5/08    A61K35/42    A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7    C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CORTI M ET AL: "Isolation and primary culture of murine alveolar type II cells" AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 14, no. 4, 1996, pages 309-315, XP008025662 ISSN: 1044-1549 cited in the application the whole document --- -/--	7-11, 15-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

5 February 2004

Date of mailing of the international search report

18/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

# INTERNATIONAL SEARCH REPORT

Inten Application No  
PCT/GB 03/03407

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHANNON J M ET AL: "Induction of alveolar type II cell differentiation in embryonic tracheal epithelium in mesenchyme-free culture." DEVELOPMENT, vol. 126, no. 8, April 1999 (1999-04), pages 1675-1688, XP002269242 ISSN: 0950-1991 cited in the application the whole document	7-11, 15-21
X	GONZALES L W ET AL: "Differentiation of human pulmonary type II cells in vitro by glucocorticoid plus cAMP." AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 283, no. 5, November 2002 (2002-11), pages L940-L951, XP002269243 ISSN: 1040-0605 First published 17-06-2002. the whole document	7-11, 15-20
A	WO 01 42425 A (BUCKLEY SUSAN A ;WARBURTON DAVID (US); DRISCOLL BARBARA (US); LOS) 14 June 2001 (2001-06-14) cited in the application example 2	11
A	FEHRENBACH H: "Alveolar epithelial type II cell: defender of the alveolus revisited." RESPIRATORY RESEARCH, vol. 2, no. 1, 2001, pages 33-46, XP002269244 ISSN: 1465-9921 cited in the application	
P,X	ALI N N ET AL: "Derivation of type II alveolar epithelial cells from murine embryonic stem cells." TISSUE ENGINEERING, vol. 8, no. 4, August 2002 (2002-08), pages 541-550, XP008025656 ISSN: 1076-3279 Publication Date: 07-08-2002 (publisher) the whole document	1-21

## INTERNATIONAL SEARCH REPORT

In ..... international application No.  
PCT/GB 03/03407

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 12 is directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern

Application No

PCT/GB 03/03407

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0142425	A	14-06-2001	AU 4520101 A	18-06-2001
			EP 1235485 A2	04-09-2002
			WO 0142425 A2	14-06-2001
			US 2002164790 A1	07-11-2002
<hr/>				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**